Recurrence of Alopecia Areata in a Patient Receiving Etanercept Injections

Posten, William; Swan, James

doi:10.1001/archderm.141.6.759

Cited by 63 publications

(43 citation statements)

References 7 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, our findings also demonstrate a rich peribulbar infiltrate with pro-inflammatory cells together with expression of TNF-α. The putative role of TNF-α in the pathogenesis of AA has led to attempts to treat AA with TNF-α antagonists like etanercept.However, previous case reports have failed to show efficacy of anti-TNF-α agents in treating AA [6, 7]. Furthermore, even recurrence of AA has been reported with infliximab as well as with adalimumab in a patient with a known history of AA [8, 9].…”

Section: Discussionmentioning

confidence: 99%

Alopecia Areata Universalis Elicited during Treatment with Adalimumab

et al. 2008

View full text Add to dashboard Cite

Adalimumab is a fully humanized recombinant anti-tumour-necrosis-factor (TNF-α) monoclonal antibody which has been approved for rheumatoid arthritis, active ankylosing spondylitis, psoriatic arthritis and Crohn’s disease. We report a case of alopecia areata (AA) universalis occurring 6 months after administration of adalimumab monotherapy in a patient with a long-standing history of psoriatic arthritis and psoriasis. The diagnosis was confirmed by a scalp biopsy which showed a peribulbar infiltrate of both CD4+ and CD8+ T cells, CD1a+ dendritic cells as well as CD68+ and CD163+ macrophages. In addition, immunofluorescence staining for TNF-α was found in the mononuclear cell infiltrate. This case suggests a complex role of TNF-α in the induction of AA.

show abstract

Section: Discussionmentioning

confidence: 99%

Alopecia Areata Universalis Elicited during Treatment with Adalimumab

et al. 2008

View full text Add to dashboard Cite

show abstract

“…However, clinically relevant manifestations are only scarcely described. The occurrence of AA during anti-TNF ␣ treatment has been reported in 5 patients to date, more frequently during anti-TNF ␣ antibody treatment [ 1 , 2 , 4 and our patient] than with etanercept [5] . It usually appears within the first 3 months of treatment, either de novo or as relapse of a previous, usually inactive AA, and may be partial or universalis.…”

mentioning

confidence: 49%

Worsening Alopecia Areata and de novo Occurrence of Multiple Halo Nevi in a Patient Receiving Infliximab

Fabre

Dereure

2008

Dermatology

View full text Add to dashboard Cite

“…In another reported case, a 44-yearold patient with universal alopecia areata did not respond to treatment with etanercept. Moreover, a patient with a history of alopecia areata whose last episode had been years earlier experienced a recurrence of his condition after starting treatment with etanercept for rheumatoid arthritis [79,80,81]. …”

Section: -Alopecia Areatamentioning

confidence: 99%

Off-Label Dermatological Uses of Etanercept Treatment

2016

J turk acad dermatol

View full text Add to dashboard Cite

Background: Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that plays an immunomodulatory role in a variety of systemic and dermatologic disease. Its blockade can be achieved by using specific inhibitors like etanercept. At present, etanercept is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and psoriasis treatment. However, it has been used with promising results in other inflammatory dermatoses. Etanercept treatment have been reported in the following dermatologic diseases: sarcoidosis, hidradenitis suppurativa, acne vulgaris, cicatricial pemphigoid, pemphigus vulgaris, Hailey-Hailey disease, Behçet' s disease, oral aphthous stomatitis, pyoderma gangrenosum, multicentric reticulohistiocytosis, apthous stomatitis, Sneddon-Wilkinson disease, acrodermatitis continua of Hallopeau, SAPHO syndrome, pityriasis rubra pilaris, vitiligo, necrobiosis lipoidica, silicone granulomas, Sweet's syndrome, atopic dermatitis, dyshidrotic eczema, toxic epidermal necrolysis, alopecia areata, centrifugal annular erythema, primary amyloidosis, erythroderma-related pruritus in Sézary syndrome, cutaneous T-cell lymphoma, inflammatory linear verrucous epidermal nevus, excessive scarring, postherpetic neuralgia, dermatomyositis, vasculitis, lupus erythematosus, and scleroderma. The vast majority of these reports are in the form of individual case reports and small case series. A growing number of published reports suggest that etanercept treatment may be effective in the treatment of numerous inflammatory skin disease outside their currently approved indications.

show abstract

Recurrence of Alopecia Areata in a Patient Receiving Etanercept Injections

Cited by 63 publications

References 7 publications

Alopecia Areata Universalis Elicited during Treatment with Adalimumab

Alopecia Areata Universalis Elicited during Treatment with Adalimumab

Worsening Alopecia Areata and de novo Occurrence of Multiple Halo Nevi in a Patient Receiving Infliximab

Off-Label Dermatological Uses of Etanercept Treatment

Contact Info

Product

Resources

About